Dr Jilly Evans
Dr Jilly Evans is a New Zealander who has led drug development programmes in Canada and the United States. She is Chief Scientific Officer and co-founder of PharmAkea Therapeutics (USA), which aims to develop small molecule drugs to treat cancer and fibrotic disease.
She was formerly a consultant at Celgene, and co-founder of Amira Pharmaceuticals, a San Diego-based biopharmaceutical company specializing in inflammatory and fibrotic diseases. Prior to these roles she spent 23 years with Merck Research Laboratories where she played a key role in the development of Singulair and Vioxx. Her knowledge of the pharmaceutical industry and her passion for the promotion of science provides important input into the core missions of the Maurice Wilkins Centre.